# A Systematic Review and Meta-Analysis of Executive Function Outcomes in Pediatric Central Nervous System Tumor Survivors

**Authors:** Esperanza Bausela Herreras

PMC · DOI: 10.62641/aep.v54i1.2053 · Actas Españolas de Psiquiatría · 2026-02-15

## TL;DR

This study finds that children and adolescents who survive central nervous system tumors often experience significant executive function deficits, especially those with Neurofibromatosis type 1 and Medulloblastoma.

## Contribution

The study provides a systematic review and meta-analysis of executive function outcomes in pediatric CNS tumor survivors using the BRIEF assessment.

## Key findings

- Children with Neurofibromatosis type 1 show significant executive function deficits, particularly in working memory and metacognition.
- Medulloblastoma survivors exhibit marked executive function deficits compared to other tumor types, especially in inhibition and regulation.
- Executive dysfunction in these survivors impacts academic, social, and emotional functioning, highlighting the need for early intervention.

## Abstract

This review aimed to determine whether executive dysfunction is a characteristic of survivors of central nervous system tumors in children and adolescents, including Astrocytoma, Neurofibromatosis-1, Medulloblastoma, and Pilocytic Astrocytoma.

A review and meta-analysis of executive function assessed with Behavior Rating Inventory of Executive Function (BRIEF) in individuals with these tumor types.

The main findings of the meta-analyses can be summarized as follows: (i) Neurofibromatosis type 1 (NF1) – BRIEF (parents): Children with NF1 show significant deficits in executive functions according to the parent-rated BRIEF, with an overall model effect size of d = 0.81 (p < 0.001). The most affected areas are working memory, monitoring, and metacognition, indicating that these deficits are consistent and clinically relevant. (ii) NF1 – BRIEF-P (parents and teachers): In this meta-analysis, the overall model effect size was d = 0.37 (p < 0.001), showing moderate but significant difficulties in executive functions. Both parents and teachers report problems in working memory and emerging metacognition, reflecting a consistent pattern across different observational contexts. (iii) Medulloblastoma vs. other tumors: Patients with medulloblastoma exhibit marked deficits in executive functions compared to other brain tumors, with an overall model effect size of d = –0.74 (p < 0.001). The most affected areas include inhibition, initiation, regulation, and metacognition, with consistent findings across the included studies.

Executive deficits are observed in individuals with brain tumors or survivors, significantly affecting their academic, social, and emotional lives. Early identification, along with educational and neuropsychological support, is essential to preventing these deficits from interfering with academic, personal, and professional functioning.

## Linked entities

- **Diseases:** Neurofibromatosis-1 (MONDO:0018975), Astrocytoma (MONDO:0019781), Medulloblastoma (MONDO:0002794), Pilocytic Astrocytoma (MONDO:0004000)

## Full-text entities

- **Genes:** NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}
- **Diseases:** Executive  dysfunction (MESH:D006331), depression (MESH:D003866), Brain Tumor (MESH:D001932), impaired  adaptive functioning (MESH:D018489), deficits in working memory (MESH:D008569), dopaminergic (MESH:D009422), Cognitive Impairment (MESH:D003072), PA (MESH:D001254), hydrocephalus (MESH:D006849), ataxia (MESH:D001259), Rare Diseases (MESH:D035583), frontal lobe damage (MESH:D001927), Epilepsy (MESH:D004827), CNS tumor (MESH:D016543), toxicities (MESH:D064420), Acute Lymphoblastic Leukemia (MESH:D054198), ADHD (MESH:D001289), -P (MESH:D002972), neurocognitive disorders (MESH:D019965), Function (MESH:D003291), reduced social skills (MESH:D019957), learning difficulties (MESH:D007859), TCP (MESH:C564276), difficulties in executive functions (MESH:D051346), Medulloblastoma (MESH:D008527), cerebellar (MESH:D002526), Executive deficits (MESH:D009461), genetic disorder (MESH:D030342), Dysexecutive  Syndrome (MESH:D013577), Autism  Spectrum Disorder (MESH:D000067877), CNS (MESH:D002493), anxiety (MESH:D001007), TBI (MESH:D000070642), ASD (MESH:D001321), Tumor (MESH:D009369), BRIEF-P (MESH:D001523), impairments in (MESH:D060825)
- **Chemicals:** dopamine (MESH:D004298), cAMP (MESH:D000242), GABA (MESH:D005680)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946733/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946733/full.md

## References

73 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946733/full.md

---
Source: https://tomesphere.com/paper/PMC12946733